Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M1 -acetylcholine receptor agonist: A randomized cross-over trial.
Bakker C, Prins S, Liptrot J, Hart EP, Klaassen ES, Brown GA, Brown A, Congreve M, Weir M, Marshall FH, Stevens J, Cross DM, Tasker T, Nathan PJ, Groeneveld GJ. Bakker C, et al. Among authors: hart ep. Br J Clin Pharmacol. 2021 Nov;87(11):4439-4449. doi: 10.1111/bcp.14872. Epub 2021 May 8. Br J Clin Pharmacol. 2021. PMID: 33891333 Free PMC article. Clinical Trial.
First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1 -receptor partial agonist for the treatment of dementias.
Bakker C, Tasker T, Liptrot J, Hart EP, Klaassen ES, Prins S, van der Doef TF, Brown GA, Brown A, Congreve M, Weir M, Marshall FH, Cross DM, Groeneveld GJ, Nathan PJ. Bakker C, et al. Among authors: hart ep. Br J Clin Pharmacol. 2021 Jul;87(7):2945-2955. doi: 10.1111/bcp.14710. Epub 2021 Feb 5. Br J Clin Pharmacol. 2021. PMID: 33351971 Free PMC article. Clinical Trial.
Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study.
Bakker C, Tasker T, Liptrot J, Hart EP, Klaassen ES, Doll RJ, Brown GA, Brown A, Congreve M, Weir M, Marshall FH, Cross DM, Groeneveld GJ, Nathan PJ. Bakker C, et al. Among authors: hart ep. Alzheimers Res Ther. 2021 Apr 21;13(1):87. doi: 10.1186/s13195-021-00816-5. Alzheimers Res Ther. 2021. PMID: 33883008 Free PMC article. Clinical Trial.
Safety, pharmacokinetics and pharmacodynamics of SBT-020 in patients with early stage Huntington's disease, a 2-part study.
van Diemen MPJ, Hart EP, Abbruscato A, Mead L, van Beelen I, Bergheanu SC, Hameeteman PW, Coppen E, Winder JY, Moerland M, Kan H, van der Grond J, Webb A, Roos RAC, Groeneveld GJ. van Diemen MPJ, et al. Among authors: hart ep. Br J Clin Pharmacol. 2021 May;87(5):2290-2302. doi: 10.1111/bcp.14656. Epub 2020 Dec 29. Br J Clin Pharmacol. 2021. PMID: 33197078 Free PMC article. Clinical Trial.
Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation.
Alvarez-Jimenez R, Baakman AC, Stevens J, Goulooze SC, Hart EP, Rissmann R, van Gerven JM, Groeneveld GJ. Alvarez-Jimenez R, et al. Among authors: hart ep. J Psychopharmacol. 2017 Feb;31(2):192-203. doi: 10.1177/0269881116681417. Epub 2016 Dec 9. J Psychopharmacol. 2017. PMID: 27927703
62 results